Bora Pharmaceuticals Co. Ltd BORAY

$2.49 -0.01 (-0.40%)

Valuation

Market cap
1,594,658,000
Revenue TTM
$610,350,000
Net income TTM
$95,700,000
P/E (trailing)
0.00
P/E (forward)
15.56
Profit margin
15.68%
Debt to equity
0.80

Trading

Volume
300
Avg volume
—
Day's range
$2.49 – $2.49
Shares out
640,425,000
Stochastic %K
1%
Beta
—
Analysts
Moderate Buy
Price target
—

Price

Company profile

Bora Pharmaceuticals Co., LTD. engages in contract development, manufacture, and sale of pharmaceuticals in Europe, the United States, Taiwan, and internationally. The company operates through Sales, CDMO, and Other segments. It manufactures and sells generic, brand, and over the counter (OTC) drugs. The company also offers contract development and manufacturing services and technical services for the development of...

Show more

Bora Pharmaceuticals Co., LTD. engages in contract development, manufacture, and sale of pharmaceuticals in Europe, the United States, Taiwan, and internationally. The company operates through Sales, CDMO, and Other segments. It manufactures and sells generic, brand, and over the counter (OTC) drugs. The company also offers contract development and manufacturing services and technical services for the development of pharmaceutical products. In addition, it provides Western pharmaceuticals, including central nervous system medications, antibiotics, and gastrointestinal medications; and nutritional and vitamin supplements, physical recovery, and health care products. The company sells its products directly to clinics, pharmacies, pharmacy chains, and drug stores, as well as through distributors to medical centers, corporate and public hospitals, and regional and district hospitals. Bora Pharmaceuticals Co., LTD. was incorporated in 2007 and is based in Taipei City, Taiwan.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Phone
886 2 27901555
Website
https://www.bora-corp.com
Address
No. 2, Ruiguang Road, 6th Floor Alley 36, Lane 26 Neihu District, Taipei, Taiwan

Latest news

No headlines yet.